Comorbid attention deficit/hyperactivity disorder and substance use disorder: Treatment considerations

Current Drug Abuse Reviews

Volumn 5, Issue 3, 2012, Pages 190-198

  Klassen, Larry J ^a,b   Bilkey, Timothy S ^c   Katzman, Martin A ^d,e,f,g   Chokka, Pratap ^h  

^a Eden Mental Health Centre   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c Ontario Bilkey ADHD Clinics   (Canada)

^d START Clinic for Mood and Anxiety Disorders   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

^g LAKEHEAD UNIVERSITY   (Canada)

^h UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Adults; Attention deficit hyperactivity disorder; Comorbidity; Conduct disorder; Diagnosis; Psychotherapy; Stimulant; Substance abuse; Substance dependence; Treatment

Indexed keywords

AMFEBUTAMONE; ATOMOXETINE; CENTRAL STIMULANT AGENT; COCAINE; LISDEXAMFETAMINE; METHYLPHENIDATE; NICOTINE; PEMOLINE; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT;

ATTENTION DEFICIT DISORDER; COMORBIDITY; CONDUCT DISORDER; COPING BEHAVIOR; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; EVIDENCE BASED PRACTICE; FEMALE; HUMAN; LIVER TOXICITY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; RISK REDUCTION; SUBSTANCE ABUSE; SUSTAINED RELEASE FORMULATION; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGE FACTORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; METHYLPHENIDATE; SUBSTANCE-RELATED DISORDERS;

EID: 84869137879     PISSN: 18744737     EISSN: 18744745     Source Type: Journal    
DOI: 10.2174/1874473711205030190     Document Type: Review

References (90)

1. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry 2006; 163: 716-23.
2. Biederman J, Wilens TE, Mick E, et al. Psychoactive substance use disorder in adults with attention-deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995; 152: 1652-8.
3. Biederman J. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. J Clin Psychiatry 2003; 64 (Suppl 11): 3-8.
4. Upadhyaya HP, Rose K, Wang W, et al. Attentiondeficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults. J Chil Adolesc Psychopharmacol 2005; 15(5): 799-809.
5. Horner BR, Scheibe KE. Prevalence and implications of attentiondeficit hyperactivity disorder among adolescents in treatment for substance abuse. J Am Acad Chil Adolesc Psychiatry 1997; 36(1): 30-6.
6. Sullivan MA, Rudnik-Levin F. Attention-deficit/hyperactivity disorder and substance abuse. Diagnostic and therapeutic considerations. Ann N Y Acad Sci 2001; 931: 251-70.
7. Schubiner H, Tzelepis A, Milberger S, et al. Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. J Clin Psychiatry 2000; 61(4): 244-51.
8. Carroll KM, Rounsaville BJ. History and significance of childhood attention deficit disorder in treatment-seeking cocaine abusers. Compr Psychiatry 1993; 34(2): 75-82.
9. Hesse M. Course of self-reported symptoms of attention deficit and hyperactivity in substance abusers during early treatment. Addict Behav 2010; 35(5): 504-6.
10. Biederman J, Monuteaux MC, Spencer T, et al. Stimulant therapy and risk for substance use disorder in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 2008; 165: 597-603.
11. Wilens TE, Biederman J, Mick E, et al. Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance abuse disorders. J Nerv Ment Dis 1997; 185: 475-82.
12. Arias AJ, Gelernter J, Chan G, et al. Correlates of co-occurring ADHD in drug-dependent subjects: Prevalence and features of substance dependence and psychiatric disorders. Addict Behav 2008; 33: 1199-207.
13. Milberger S, Biederman J, Faraone SV, et al. Associations between ADHD and psychoactive substance use disorders. Findings from a longitudinal study of high-risk siblings of ADHD children. Am J Addict 1997; 6(4): 318-29.
14. Ribeiro SN, Jennen-Steinmetz C, Schmidt MH, et al. Nicotine and alcohol use in adolescent psychiatric inpatients: association with diagnoses, psychosocial factors, gender and age. Nord J Psychiatry 2008; 62(4): 315-21.
15. Wilens TE, Biederman J, Mick E. Does ADHD affect the course of substance abuse? Findings from a sample of adults with and without ADHD. Am J Addict 1998; 7: 156-63.
16. Wilens TE, Kwon A, Tanguay S, et al. Characteristics of adults with attention deficit hyperactivity disorder plus substance use disorder: the role of psychiatric comorbidity. Am J Addict 2005; 14: 319-27.
17. Biederman J, Wilens TE, Mick E, et al. Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biol Psychiatry 1998; 44: 269-73.
18. Volkow ND, Wang GJ, Newcorn J, et al. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2007; 64: 932-40.
19. Volkow ND, Wang GJ, Newcorn J, et al. Brain dopamine transporter levels in treatment and drug naïve adults with ADHD. Neuroimage 2007; 34: 1182-90.
20. Volkow ND, Wang GJ, Kollins SH, et al. Evaluating dopamine reward pathway in ADHD. Clinical implications. JAMA 2009; 302: 1084-91.
21. Feltenstein MW, See RE. The neurocircuitry of addiction: an overview. Br J Pharmacol 2008; 154: 261-74.
22. Volkow ND, Fowler JS, Wang GJ, et al. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 2004; 9: 557-69.
23. McClernon FJ, Kollins SH. ADHD and smoking. From genes to brain to behavior. Ann N Y Acad Sci 2008; 1141: 131-47.
24. Volkow ND, Wang GJ, Fischman MW, et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997; 386: 827-30.
25. Biederman J, Petty CR, Wilens TE, et al. Familial risk analyses of attention deficit hyperactivity disorder and substance use disorders. Am J Psychiatry 2008; 165: 107-15.
26. Monuteaux MC, Faraone SV, Hammerness P, et al. The familial association between cigarette smoking and ADHD: a study of clinically referred girls with and without ADHD, and their families. Nicotine Tob Res 2008; 10(10): 1549-58.
27. Milberger S, Biederman J, Faraone SV, et al. Further evidence of an association between attention-deficit/hyperactivity disorder and cigarette smoking. Findings from a high-risk sample of siblings. Am J Addict 1997; 6(3): 205-17.
28. Biederman J, Petty CR, Monuteaux MC, et al. Familial risk analysis of the association between attention-deficit/hyperactivity disorder and psychoactive substance use disorder in female adolescents: a controlled study. J Child Psychol Psychiatry 2009; 50(3): 352-8.
29. Milberger S, Faraone SV, Biederman J, et al. Familial risk analysis of the ssociation between attention-deficit/hyperactivity disorder and psychoactive substance use disorders. Arch Pediatr Adolesc Med 1998; 152(10): 945-51.
30. Potter AS, Newhouse PA. Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder. Pharmacol Biochem Behav 2008; 88: 407-17.
31. Volkow ND, Wang GJ, Fowler JS, et al. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57: 1410-5.
32. Brook D, Brook JS, Zhang C, et al. The association between attention deficit hyperactivity disorder in adolescence and substance use disorders in adulthood. Arch Pediat Adolesc Med 2010; 164(10): 930-4.
33. Elkins IJ, McGue M, Iacono WG. Prospective effects of attentiondeficit/hyperactivity disorder, conduct disorder, and sex on adolescent substance use and abuse. Arch Gen Psychiatry 2007; 64(10): 1145-52.
34. Fergusson DM, Horwood LJ, Ridder EM. Conduct and attentional problems in childhood and adolescence and later substance use, abuse and dependence: results of a 25-year longitudinal study. Drug Alcohol Depend 2007; 88 Suppl 1: S14-S26.
35. Szobot CM, Rohde LA, Bukstein O, et al. Is attentiondeficit/hyperactivity disorder associated with illicit substance use disorders in male adolescents? A community-based case-control study. Addiction 2007; 102(7): 1122-30.
36. Kollins SH, McClernon FJ, Fuemmeler BF. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry 2005; 62(10): 1142-7.
37. Molina BS, Pelham WE Jr. Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. J Abnorm Psychol 2003; 112(3): 497-507.
38. Barkley RA, Fischer M, Smallish L, et al. Young adult follow-up of hyperactive children: antisocial activities and drug use. J Child Psychol Psychiatr 2004; 45: 195-211.
39. Burke JD, Loeber R, Lahey BB. Which aspects of ADHD are associated with tobacco use in early adolescence? J Child Psychol Psychiatry 2001; 42(4): 493-502.
40. Milberger S, Biederman J, Faraone SV, et al. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Chil Adolesc Psychiatry 1997; 36(1): 37-44.
41. Biederman J, Monuteaux MC, Mick E, et al. Is cigarette smoking a gateway to alcohol and illicit drug use disorders? A study of youths with and without attention deficit-hyperactivity disorder. Biol Psychiatry 2006; 59: 258-64.
42. Wilens TE, Faraone SV, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003; 111: 179-85.
43. Biederman J, Wilens TE, Mick E, et al. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999; 104: e20-e24.
44. Katusic SK, Barbaresi WJ, Colligan RC, et al. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a populationbased, birth cohort study. J Chil Adolesc Psychopharmacol 2005; 15(5): 764-76.
45. Wilens TE, Adamson J, Monuteaux MC, et al. Effect of prior stimulant treatment for attention-deficit hyperactivity disorder in the subsequent risk for cigarette smoking, alcohol, and drug use disorders in adolescent girls. Arch Pediatr Adolesc Med 2008; 162: 916-21.
46. Faraone SV, Biederman J, Wilens TE, et al. A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults. Psychol Med 2007; 37: 1743-52.
47. Mannuzza S, Klein RG, Truong NL, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Pschiatr 2008; 165: 604-9.
48. Barkley RA, Fischer M, Smallish L, et al. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics 2003; 111: 97-109.
49. Volkow ND, Swanson JM. Does childhood treatment of ADHD with stimulant medication affect substance abuse in adulthood? Am J Psychiatry 2008; 165: 553-5.
50. Thanos PK, Michaelides M, Benveniste H, et al. Effects of chronic oral methylphenidate on cocaine self-administration and striatal dopamine D2 receptors in rodents. Pharmacol Biochem Behav 2007; 87: 426-33.
51. Winhusen TM, Somoza EC, Brigham GS, et al. Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-bind, placebo-controlled trial. J Clin Psychiatry 2010; 71(12): 1680-8.
52. Levin FR, Evans SM, Brooks DJ, et al. Treatment of methadonemaintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 2006; 81(2): 137-48.
53. Levin FR, Evans SM, Brooks DJ, et al. Treatment of cocaine dependent treatment seekers with adults ADHD: double-blind comparison of methylphenidate and placebo. Dug Alcohol Depend 2007; 87: 20-9.
54. Schubiner H, Saules KK, Arfken CL, et al. Double-blind placebocontrolled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 2002; 10: 286-94.
55. Castaneda R, Levy R, Hardy M, et al. Long-acting stimulants for the treatment of attention-deficit disorder in cocaine-dependent adults. Psychiatr Serv 2000; 51(2): 169-71.
56. Levin FR, Evans SM, McDowell DM, et al. Methylphenidate treatment for cocaine abusers with adults' attentiondeficit/hyperactivity disorder: a pilot study. J Clin Psychiatry 1998; 59: 300-5.
57. Somoza EC, Winhusen TM, Bridge TP, et al. An open-label pilot study of methylphenidate in the treatment of cocaine dependent patients with adult attention deficit/hyperactivity disorder. J Addict Dis 2004; 23: 77-92.
58. Szobot CM, Rohde LA, Katz B, et al. A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder. Braz J Med Biol Res 2008; 41(3): 250-7.
59. Carpentier PJ, de Jong CAJ, Dijkstra BAG, et al. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction 2004; 100: 1868-74.
60. Biederman J, Spencer T. Methylphenidate in treatments of adults with Attention-Deficit/Hyperactivity Disorder. J Atten Disord 2002; 6 Suppl 1: S101-S107.
61. Volkow ND, Ding YS, Fowler JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995; 52: 456-63.
62. Grabowski J, Roache JD, Schmitz JM, et al. Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol 1997; 17: 485-8.
63. Grabowski J, Rhoades H, Schmitz J, et al. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 2001; 21(5): 522-6.
64. Grabowski J, Shearer J, Merrill J, et al. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 2004; 29(7): 1439-64.
65. Roache JD, Grabowski J, Schmitz JM, et al. Laboratory measures of methylphenidate effects in cocaine-dependent patients receiving treatment. J Clin Psychoparmacol 2000; 20: 61-8.
66. Wilens TE, Adler LA, Weiss MD, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend 2008; 96(1-2): 145-54.
67. Levin FR, Mariani JJ, Secora A, et al. Atomoxetine treatment for cocaine abuse and adult attention-deficit hyperactivity disorder (ADHD): a preliminary open trial. J Dual Diagn 2009; 5: 41-56.
68. Riggs PD, Thompson LL, Mikulich SK, et al. An open trial of pemoline in drug-dependent delinquents with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1996; 35: 1018-24.
69. Riggs PD, Hall SK, Mikulich-Gilbertson SK, et al. A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents. J Am Acad Chil Adolesc Psychiatry 2004; 43: 420-9.
70. Covey LS, Hu MC, Winhusen T, et al. OROS-methylphenidate or placebo for adult smokers with attention deficit hyperactivity disorder: racial/ethnic differences. Drug Alcohol Depend 2010; 110: 156-9.
71. Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 2009; 23: 419-27.
72. Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Chil Adolesc Psychiatry 2008; 47: 21-31.
73. United States Department of Health and Human Services Substance Abuse & Mental Health Services Administration [homepage on the Internet]. Results from the 2008 National Survey on Drug Use and Health: National Findings. Cited 2009 Dec 8. Available from: http://oas.samhsa.gov/NSDUH/2K8NSDUH/tabs/toc.htm
74. Swanson JM, Volkow ND. Increasing use of stimulants warns of potential abuse. Nature 2008; 453: 586.
75. Wilens TE. Impact of ADHD and its treatment on substance abuse in adults. J Clin Psychiatry 2004; 65 (Suppl 3): 38-45.
76. Tiet QQ, Mausbach B. Treatments for patients with dual diagnosis: a review. Alcohol Clin Exp Res 2007; 31: 513-36.
77. Dalley JW, Fryer TD, Aigbirhio FI, et al. Modelling human drug abuse and addiction with dedicated small animal positron emission tomography. Neuropharmacology 2009; 56 (Suppl 1): 9-17.
78. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003; 160: 1909-18.
79. Parasrampuria DA, Schoedel KA, Schuller R, et al. Do formulation differences alter abuse liability of methylphenidate? A placebocontrolled, randomized, double-blind, crossover study in recreational drug users. J Clin Psychopharmacol 2007; 27: 459-67.
80. Heiligenstein E, Johnston HF, Nielsen JK. Pemoline therapy in college students with attention deficit hyperactivity disorder: a retrospective study. J Am Coll Health 1996; 45: 35-9.
81. Bostic JQ, Biederman J, Spencer TJ, et al. Pemoline treatment of adolescents with attention deficit hyperactivity disorder: a shortterm controlled trial. J Child Adolesc Psychopharmacol 2000; 10: 205-16.
82. Bukstein O. Substance abuse in patients with attentiondeficit/hyperactivity disorder. Medscape J Med 2008; 10: 24-33.
83. Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamphetamine dimesylate in adults with attentiondeficit/hyperactivity disorder. J Clin Psychiatry 2008; 69: 1364-73.
84. Shire Canada Inc. Vyvanse (lisdexamfetamine dimesylate capsules) Product Monograph. Date of Preparation: 14 April 2010.
85. Baillie AJ, Stapinski L, Crome E, et al. Some new directions for research on psychological interventions for comorbid anxiety and substance use disorders. Drug Alcohol Rev 2010; 29: 518-24.
86. Hides L, Samet S, Lubman DI. Cognitive behaviour therapy (CBT) for the treatment of co-occurring depression and substance use: current evidence and directions for future research. Drug Alcohol Rev 2010; 29(5): 508-17.
87. Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry 2010; 10: 67.
88. Virta M, Salakari A, Antila M, et al. Short cognitive behavioral therapy and cognitive training for adults with ADHD-a randomized controlled pilot study. Neuropsychiatr Dis Treat 2010; 6: 443-53.
89. Safren SA, Sprich S, Mimiaga MJ, et al. Cognitive behavioral therapy vs relaxation with educational support for medicationtreated adults with ADHD and persistent symptoms: a randomized controlled trial. JAMA 2010; 304(8): 875-80.
90. Aviram RB, Rhum M, Levin FR. Psychotherapy of adults with comorbid attention-deficit/hyperactivity disorder and psychoactive substance use disorder. J Psychother Prac Res 2001; 10: 179-86.